Maimon Research LLC is a long established boutique consulting company specializing in health technology assessment, together with advising and implementing market access strategies to support pharmaceutical products and devices over their life cycle.

The focus of Maimon Research is on developing claims for pharmaceutical products and devices that are credible, evaluable and replicable.

This sets Maimon Research apart from other health technology assessment consultants. Unlike competitors, Maimon Research offers a unique and methodologically acceptable approach to the validation and replication of health technology claims.

This approach puts to one side the modeling of non-testable claims based on the construction of reference case lifetime imaginary worlds which, unfortunately, have come to dominate the health technology assessment literature over the past 30 years, in favor of credible claims which meet the standards of normal science. This technology assessment ‘meme’ is an intellectual and analytical dead end. It has to be abandoned in favor of value assessment frameworks that make sense for formulary committees.

The purpose of this website is to introduce prospective clients to the case made in a number of commentaries authored by Dr Paul C Langley, Director, Maimon Research for the standards required to make product claims that meet those of normal science. Links are provided to over 40 commentaries which have evaluated ICER claims as well as those focused on the development of evidence platforms and patient centric outcomes measures.

Normal science is not new ......

 "No human investigation can be termed true   science if it is not capable of mathematical demonstration. If you say that the sciences which begin and end in the mind are true, then it is not to be conceded, but is denied for many reasons, and chiefly the fact that the test of experience is absent from these exercises of the mind, and without it nothing can be certain" (Leonardo da Vinci  d. 1519)